Home
Heart Failure

Heart Failure

A Race Against Time: Accelerating the Adoption of GDMT in Heart Failure

Antoni Bayés-Genís Lisa Anderson Stephen J Greene

Not accredited

Published: 03/06/2024

Recall guideline recommendations for the use of NT-proBNP in heart failure
Describe current practices in heart failure diagnosis and the impact on treatment outcomes
Develop an optimised approach to the timely diagnosis and management of heart failure

An Expert Approach to Cardio-Renal Protection in CKD

James Burton Navdeep Tangri David Wheeler et al

2.00 EBAC

Published: 26/06/2024

Recall clinical evidence and guidelines for the management of CKD patients without diabetes
Describe current gaps and barriers in evidence-based management for CKD without diabetes
Apply evidence based-management strategies to a case study
Use expert-led guidance to develop an optimal management approach to CKD patients without diabetes

Implementing Heart Failure Guidelines with Collaborative Care

Carolyn Lam Mark Petrie Stephen J Greene et al

Not accredited

Published: 15/09/2023

Appraise new updates in heart failure guideline-directed medical therapy (GDMT)
Apply latest guideline recommendations to patient cases
Describe barriers preventing early initiation of GDMT
Identify the roles of nurses and other healthcare professionals to achieve optimal heart failure therapy
Identify the importance of the nurse/cross-functional team

The Advancing Management of Transthyretin Amyloidosis

Julian Gillmore Martha Grogan Laura Obici et al

1.00 EBAC

Published: 16/10/2023

To differentiate ATTR phenotypes based on presenting signs and symptoms.
To select appropriate tests to monitor symptomatic ATTR-cm from imaging, biomarker, functional and QoL assessments.
To recall how to identify disease progression across ATTR-cm.
To describe the different disease modifying treatments for ATTR including novel agents.

Overcoming the Challenges in Optimising GDMT in HF

Gianluigi Savarese Stephen J Greene Mark Petrie

Not accredited

Published: 26/06/2023

Appraise the urgency needed in rapid initiation of GDMT to improve HF outcomes.
Recognise barriers preventing the use of GDMT in current practice.
Identify strategies needed to drive implementation of GDMT in clinical practice.

Hyperkalaemia in Cardiorenal Disease – A Case Based Discussion

James Burton Shelley Zieroth Clara Bonanad Lozano et al

Not accredited

Published: 16/05/2023

Explain the relationship between sub-optimal RAASi therapy and poor cardio-renal outcomes
Identify patients who would benefit from anti-hyperkalaemia medications
Select appropriate anti-hyperkalaemia treatments across a range of patient profiles
Adopt anti-hyperkalaemia medications as an approach to prolong optimal RAASi therapy
Summarise current guideline recommendations on the use of potassium binding agents

Heart Failure

A Race Against Time: Accelerating the Adoption of GDMT in Heart Failure

Antoni Bayés-Genís Lisa Anderson Stephen J Greene

Not accredited

Published: 03/06/2024

Recall guideline recommendations for the use of NT-proBNP in heart failure
Describe current practices in heart failure diagnosis and the impact on treatment outcomes
Develop an optimised approach to the timely diagnosis and management of heart failure

An Expert Approach to Cardio-Renal Protection in CKD

James Burton Navdeep Tangri David Wheeler et al

2.00 EBAC

Published: 26/06/2024

Recall clinical evidence and guidelines for the management of CKD patients without diabetes
Describe current gaps and barriers in evidence-based management for CKD without diabetes
Apply evidence based-management strategies to a case study
Use expert-led guidance to develop an optimal management approach to CKD patients without diabetes

Examining a Complex Heart Failure Case

Andrew JS Coats Katherine Tuttle Richard Hobbs et al

1.00 EBAC

Published: 10/03/2023

Identify individuals likely to have HFpEF from initial presentation
Refer suspected individuals for specialist assessment
Initiate GDMT for HF as soon as patients are stable
Initiate GDMT in HF regardless of EF and phenotype
Initiate shared decision-making on complex HF patients with other members of the multidisciplinary team including cardiologists, GPs, nephrologists and diabetologists

Heart Failure Management in a Changing Paradigm

Andrew JS Coats Shelley Zieroth Javed Butler et al

1.00 EBAC

Published: 16/06/2022

Recall the utility of EF in heart failure treatment, patient selection and treatment response
Identify alternative measures to EF for the purposes HF severity and therapeutic efficacy
Incorporate quality of life measures for assessing therapeutic efficacy in HF
Recall outcomes from heart failure trials from recent congress and publications and their impact on practice

HFO 2022 - Session 1.2 Practical Theory & Hot Topics: The Complex Patient

1.00 EBAC

Published: 01/06/2022

Select foundational and advanced management strategies in complex patients
Discuss the validity of using ejection fraction to determine optimal treatment strategies
Assess the likely impact of health technology on future practice
Identify the underlying causes of heart failure
Select appropriate interventional and device-based treatments for treating underlying causes of heart failure
Assess the impact of the multidisciplinary team on heart failure outcomes
Discuss the importance of using quality of life and patient self-assessed measures relative to hard clinical end points

HFO 2022 - Session 1.4 Practical Theory & Hot Topics: Transitioning Care and Monitoring Technology

1.00 EBAC

Published: 01/06/2022

Select foundational and advanced management strategies in complex patients
Discuss the validity of using ejection fraction to determine optimal treatment strategies
Assess the likely impact of health technology on future practice
Identify the underlying causes of heart failure
Select appropriate interventional and device-based treatments for treating underlying causes of heart failure
Assess the impact of the multidisciplinary team on heart failure outcomes
Discuss the importance of using quality of life and patient self-assessed measures relative to hard clinical end points

Heart Failure

Incorporating GDMT and PRO Endpoints for Personalised HF Management

Andrew JS Coats Mikhail Kosiborod Shelley Zieroth et al

1.00 EBAC

Published: 23/03/2023

Review current GDMT in HFrEF and HFpEF
Describe the relationship between initiation of GDMT and HF outcomes
Prescribe GDMT according to current international recommendations
Recall the elements of the Kansas City Cardiomyopathy Questionnaire
Describe the clinical studies that support the use of functional and QoL measures in practice
Initiate quality of life and functional improvement measures in routine practice
Initiate SGLT-2 inhibitors in patients presenting with De novo HF and in patients already on other GDMT
Adopt shared decision-making with HF patients

Obstructive Hypertrophic Cardiomyopathy: Getting It Right First Time

Marc Dweck Milind Y Desai Carolyn Ho et al

1.00 EBAC

Published: 06/02/2023

Recall the general approach to diagnosis and stratification of HCM according to the latest guidelines and expert opinion
Apply advanced echocardiographic methodologies to equivocal HCM diagnoses
Select appropriate imaging modalities to facilitate accurate risk stratification
Stratify patients based on specific risk features and disease severity
Choose suitable treatment modalities for patients based on specific disease features and severity

Hypertrophic Cardiomyopathy in Review: Highlights from HFA 2021

Perry Elliott

0.50 AMA PRA Credit

Published: 04/11/2021

Identify patients likely to benefit from invasive procedures versus pharmacological treatment
Stratify individuals with HCM signs and symptoms for subsequent investigation and/or genetic screening

Examining a Complex Heart Failure Case

Andrew JS Coats Katherine Tuttle Richard Hobbs et al

1.00 EBAC

Published: 10/03/2023

Identify individuals likely to have HFpEF from initial presentation
Refer suspected individuals for specialist assessment
Initiate GDMT for HF as soon as patients are stable
Initiate GDMT in HF regardless of EF and phenotype
Initiate shared decision-making on complex HF patients with other members of the multidisciplinary team including cardiologists, GPs, nephrologists and diabetologists

Hypertrophic Cardiomyopathy: Application of Emerging Data and Genetic Testing in Clinical Practice

Carolyn Ho

0.75 AMA PRA Credit

Published: 17/02/2022

Recall the efficacy and safety of existing HCM treatments
Summarise results from ongoing trials with experimental treatments
Stratify individuals with HCM signs and symptoms for subsequent investigation and/or genetic screening

Hyperkalaemia in Cardiorenal Disease – A Case Based Discussion

James Burton Shelley Zieroth Clara Bonanad Lozano et al

Not accredited

Published: 16/05/2023

Explain the relationship between sub-optimal RAASi therapy and poor cardio-renal outcomes
Identify patients who would benefit from anti-hyperkalaemia medications
Select appropriate anti-hyperkalaemia treatments across a range of patient profiles
Adopt anti-hyperkalaemia medications as an approach to prolong optimal RAASi therapy
Summarise current guideline recommendations on the use of potassium binding agents

Heart Failure

Learning objectives

Learning objectives

Learning objectives

Learning objectives

Learning objectives

Learning objectives

Heart Failure

Learning objectives

Learning objectives

Learning objectives

Learning objectives

Learning objectives

Learning objectives

Heart Failure

Learning objectives

Learning objectives

Learning objectives

Learning objectives

Learning objectives

Learning objectives